Authors
Fernando Sarmiento Quintero, Ana María Castañeda Figueroa, Diana Victoria Mora Quintero, Claudia Patricia Sánchez Franco, Lina Eugenia Jaramillo Barberi, Sergio Andrés Prado Baquero, Marco Alberto Suárez Urueña, Andrea Natalia Pedraza Peña, Stephanía Peña Hernández, Karol Andrea Martínez Portilla, Lina Baños Rocha, Luz Esthella Tovar Correa, Diana Catalina López Mora, Catalina Pallejá López, Diana Paola Sánchez Hernández, Mónica María Contreras Ramírez, Catalina Ortiz Piedrahita, Claudia Liliana Losada Gómez, Alejandra Wilches Luna, Diana María Quimbayo Wilches, Verónica Botero Osorio, Rafael Milanés Romero, Andrés Enríquez Calvache, Melquisedec Vargas Sandoval, Fernando Medina Monroy, Hugo Laignelet Hernández, Wilson Daza Carreño, José Fernando Vera Chamorro, Ailim Margarita Carias Domínguez, Johana Hincapié Butto, Maira Patricia Sánchez Pérez, Carlos Cuadros Mendoza, Otto Calderón Guerrero, María Mercedes Naranjo Vergara, Clara Eugenia Plata García, Luis Carlos Ramírez Urrego, Rodrigo De Vivero Camacho, Sandra Helena Paipilla Monroy, Luz Eugenia Aragón Calvo, Mariastella Serrano
Published in
Crohn's & colitis 360. Volume 8. Issue 3. Pages otag038. Epub Aug 31, 2026.
Abstract
Inflammatory bowel disease (IBD) has significantly increased over the past two decades. However, registries in Latin America remain scarce, prompting the creation of the Colombian pediatric IBD registry for patients under 18 years of age, designed as a continuous and periodically assessed database.
A descriptive, longitudinal, ambispective, and multicenter observational study was conducted in children aged 0-18 years between January 1999 and December 2021. The analysis was performed based on the age of onset (Paris classification), with subdivisions for very early onset and phenotypes using the Pediatric IBD-classes algorithm. Data were collected in REDCap and analyzed with STATA 15.1.
A total of 209 patients were included, 54.5% male. The median age at diagnosis was 12.3 years (IQR 8.5-14.6). Phenotype distribution included: 104 (53.06%) typical ulcerative colitis (TUC), 52 (26.53%) Crohn's disease (CD), 18 (9.18%) unclassifiable IBD (U-IBD), 11 (5.61%) colonic Crohn's disease (CCD), and 11 (5.61%) atypical ulcerative colitis (AUC). The median time to diagnosis was 6.6 months, and treatment began after a median of 11.2 days. Coffee-cultivation zone 39%. Extraintestinal manifestations were reported in 43.9% of cases. Initial treatments included mesalamine ± steroids (35.86%), immunomodulators ± steroids (32%), exclusive/partial enteral nutrition (11.41%), and biologics ± immunomodulators (20.65%), which increased to 57.7% during follow-up. Relapse occurred in 53.26% of patients, while 35.32% achieved remission.
This registry highlights the increasing incidence of pediatric IBD in Latin America, providing valuable insights into clinical presentations, diagnostic delays, treatment strategies, and outcomes, while revealing regional and global disparities.
PMID:
42719817
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0